SCHEMBL13614219

SCHEMBL13614219

CC(C)(C)OC(=O)N[C@@](C)(CO)CCc1ccccc1

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CA12 O43570 1/20 0.51
CA1 P00915 1/20 0.51
CA7 P43166 1/20 0.51
CA14 Q9ULX7 1/20 0.51
CTSS P25774 5/20 0.46
CTSK P43235 3/20 0.46
AKT1 P31749 2/20 0.46
CTSL P07711 3/20 0.44
CTSB P07858 3/20 0.44
ATM Q13315 1/20 0.44
SIGMAR1 Q99720 3/20 0.44
NPC1 O15118 1/20 0.43
MAPT P10636 1/20 0.43
RAB9A P51151 1/20 0.43
IDO1 P14902 1/20 0.43
SSTR4 P31391 1/20 0.42
PPARA Q07869 2/20 0.41
PPARG P37231 1/20 0.41
SYK P43405 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4817662 0.89 FFAR1 (0.50) NPC1MAPTRAB9APPARG
SCHEMBL4816575 0.88 FFAR1 (0.51) PPARAPPARG
SCHEMBL12721376 0.87 CTSS (0.43) CA12CA1CA7CA14CTSS
SCHEMBL1625903 0.87 CTSS (0.43) CA12CA1CA7CA14CTSS
SCHEMBL12721396 0.87 NPC1 (0.44) CA12CA1CA7CA14NPC1
SCHEMBL2215358 0.87 CA12 (0.49) CA12CA1CA7CA14CTSS
SCHEMBL6468038 0.87 CA12 (0.49) CA12CA1CA7CA14CTSS
SCHEMBL19790268 0.87 CA12 (0.49) CA12CA1CA7CA14CTSS
SCHEMBL688475 0.86 PPARG (0.47) PPARAPPARG
SCHEMBL567236 0.84 NPC1 (0.47) CA12CA1CA7CA14NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7612238-B2 Such as (R)-2-amino-2-methyl-4-[4-(4,4,5,5,5-pentafluoro-pentyloxy)-phenyl]-butan-1-ol hydrochloride for treatment of disorders or diseases mediated by lymphocytes, and for treating acute or chronic transplant rejection or T-cell-mediated inflammatory or autoimmune diseases NOVARTIS AG (CH) 2009-11-03 US disclosed